Institute of Genomics and Integrative Biology (IGIB), constituent lab of CSIR, has signed a MoU with TATA Sons for licensing of KNOWHOW for FELUDA in order to execute rapid diagnosis of COVID-19. The MoU aims to provide license which will enable transfer of the knowledge for scaling up the KNOWHOW in the form of a kit in order to employ it for COVID-19 testing on ground as soon as possible. Hence, as per MoU, CSIR-IGIB will now work along with TATA Sons to bring FELUDA for widespread use at the earliest.
Click Here To Get Test Series For SBI PO 2020
FNCAS9 Editor Linked Uniform Detection Assay (FELUDA) has been designed to alleviate the current COVID-19 situation and cater to mass testing. The main advantages of FELUDA is its affordability, relative ease of use as well as non-dependency on expensive Q-PCR machines.
Did you know India is home to some of the tallest and most powerful dams…
Indian Railways has achieved an important milestone by launching the country’s first LNG–Diesel dual-fuel DEMU…
Andhra Pradesh has taken a strong and positive step to support women entrepreneurs by planning…
The world’s two most populous nations and Asia’s largest economies have reached a historic trade…
In February 2026, Elon Musk achieved a historic milestone by becoming the first individual on…
Shri Divakar Jayant, a distinguished officer of the Indian Naval Armament Service (INAS), officially assumed…